Association of uric acid levels with the development of metabolic dysfunction-associated and metabolic and alcohol-related/associated steatotic liver disease: a study on Japanese participants undergoing health checkups

被引:0
|
作者
Fukuda, Tatsuya [1 ,2 ,3 ,4 ]
Akihisa, Taro [2 ,4 ]
Okamoto, Takahiro [1 ]
Fukaishi, Takahiro
Kawakami, Akio [4 ]
Tanaka, Makoto [5 ]
Yamada, Tetsuya [3 ]
Monzen, Koshiro [4 ]
机构
[1] Mirraza Shinjuku Tsurukame Clin, Tokyo 1600022, Japan
[2] Tokyo Metropolitan Okubo Hosp, Dept Endocrinol & Metab, 2-44-1 Kabuki-cho,Shinjyuku ku, Tokyo 1608488, Japan
[3] Inst Sci Tokyo, Grad Sch Med & Dent Sci, Dept Mol Endocrinol & Metab, Tokyo 1138510, Japan
[4] Shinjuku Tsurukame Clin, Tokyo 1510053, Japan
[5] Koganei Tsurukame Clin, Tokyo 1840004, Japan
关键词
Metabolic dysfunction-associated steatotic liver disease (MASLD); Nonalcoholic fatty liver disease (NAFLD); Metabolic and alcohol related/associated liver disease (MetALD); Alcohol consumption; Uric acid; INSULIN-RESISTANCE; HYPERURICEMIA; INDEX; RISK;
D O I
10.1507/endocrj.EJ24-0622
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Hyperuricemia reflects increased insulin resistance, and uric acid (UA) may serve as a predictive marker for the development of metabolic dysfunction-associated steatotic liver disease (MASLD); however, few studies have investigated this condition in the Japanese population. Thus, this retrospective observational study aimed to investigate the association of hyperuricemia with the risk of MASLD or metabolic and alcohol-related liver disease (MetALD) in individuals undergoing health checkups. A cross-sectional analysis was performed on 58,110 individuals, dividing them into quartile groups according to UA values for men and women (Q1 being the lowest and Q4 being the highest), and examining the complication rate of MASLD/MetALD. Subsequently, among 22,364 individuals without MASLD/MetALD, the relationship between UA at baseline and MASLD/MetALD development during follow-up was investigated using Cox proportional hazard models. In the cross-sectional analysis, the higher UA group had a higher complication rate of MASLD/MetALD in both men and women. In the follow-up analysis, both genders in the higher UA quartiles had a significantly higher incidence of MASLD/ MetALD than those in the lower quartiles. Multivariate Cox proportional hazards analysis revealed that Q4 had a significantly higher hazard ratio than Q1 for both genders. These trends were the same in the time-dependent body mass index (BMI) model, which incorporated BMI as a time-dependent variable. High UA levels may serve as a predictive marker for MASLD/ MetALD development. UA monitoring during health checkups could enable early detection and provision of intervention, improving patient outcomes.
引用
收藏
页数:17
相关论文
共 50 条
  • [1] Extent to which weight loss contributes to improving metabolic dysfunction-associated and metabolic and alcohol related/associated steatotic liver disease: a study on Japanese participants undergoing health checkups
    Fukuda, Tatsuya
    Okamoto, Takahiro
    Fukaishi, Takahiro
    Kawakami, Akio
    Tanaka, Makoto
    Yamada, Tetsuya
    Monzen, Koshiro
    FRONTIERS IN ENDOCRINOLOGY, 2024, 15
  • [2] Dietary fructose: from uric acid to a metabolic switch in pediatric metabolic dysfunction-associated steatotic liver disease
    Faienza, Maria Felicia
    Cognetti, Eleonora
    Farella, Ilaria
    Antonioli, Alessandro
    Tini, Sabrina
    Antoniotti, Valentina
    Prodam, Flavia
    CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION, 2024,
  • [3] The association between alcohol consumption and cardiometabolic factors and liver fibrosis in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated liver disease
    Sogabe, Masahiro
    Okahisa, Toshiya
    Kagawa, Miwako
    Kashihara, Takanori
    Shinomiya, Ryo
    Miyake, Takanori
    Kawaguchi, Tomoyuki
    Yokoyama, Reiko
    Kagemoto, Kaizo
    Kida, Yoshifumi
    Okada, Yasuyuki
    Tomonari, Tetsu
    Kawano, Yutaka
    Sato, Yasushi
    Nakasono, Masahiko
    Takayama, Tetsuji
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 60 (11-12) : 1587 - 1598
  • [4] Metabolic dysfunction-associated steatotic liver disease: A silent pandemic
    Samanta, Arghya
    Sen Sarma, Moinak
    WORLD JOURNAL OF HEPATOLOGY, 2024, 16 (04)
  • [5] Metabolic dysfunction-associated steatotic liver disease and the heart
    Driessen, Stan
    Francque, Sven M.
    Anker, Stefan D.
    Cabezas, Manuel Castro
    Grobbee, Diederick E.
    Tushuizen, Maarten E.
    Holleboom, Adriaan G.
    HEPATOLOGY, 2023,
  • [6] Metabolic dysfunction-associated steatotic liver disease and atherosclerosis
    Castillo-Nunez, Yulino
    Almeda-Valdes, Paloma
    Gonzalez-Galvez, Guillermo
    Arechavaleta-Granell, Maria del Rosario
    CURRENT DIABETES REPORTS, 2024, 24 (07) : 158 - 166
  • [7] Association of the Metabolic Dysfunction-Associated Fatty Liver Disease with Serum Uric Acid-to-Creatinine Ratio
    Han, A. Lum
    Lee, Hee Kyung
    METABOLIC SYNDROME AND RELATED DISORDERS, 2022, 20 (07) : 370 - 376
  • [8] Menopause and metabolic dysfunction-associated steatotic liver disease
    Polyzos, Stergios A.
    Goulis, Dimitrios G.
    MATURITAS, 2024, 186
  • [9] Association of metabolic dysfunction-associated steatotic liver disease with erosive esophagitis development: a longitudinal observational study
    Sogabe, Masahiro
    Okahisa, Toshiya
    Kagawa, Miwako
    Sei, Motoko
    Ueda, Hiroyuki
    Yokoyama, Reiko
    Kagemoto, Kaizo
    Tanaka, Hironori
    Kida, Yoshifumi
    Nakamura, Fumika
    Tomonari, Tetsu
    Okamoto, Koichi
    Kawano, Yutaka
    Miyamoto, Hiroshi
    Sato, Yasushi
    Nakasono, Masahiko
    Takayama, Tetsuji
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 (06) : 1107 - 1114
  • [10] Association Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Thyroid Cancer
    Moon, Sang Yi
    Son, Minkook
    Cho, Jung-Hwan
    Kim, Hye In
    Han, Ji Min
    Bae, Ji Cheol
    Suh, Sunghwan
    THYROID, 2025, 35 (01) : 79 - 86